Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/jspui/handle/123456789/13494 |
Resumo: | The study had as objective to evaluate the zinc status by means of dietary intake, zinc in plasma and in erythrocytes and the metallothionein gene expression in patients with atherosclerosis in use of rosuvastatin. The research involved 27 adult and elderly patients of both genders with atherosclerosis that were treated with rosuvastatin (10mg/day) during 4 months. We performed the dosage of lipids, glucose, AST and ALT, ultrasensitive C-reactive protein (hsCRP), plasmatic and erythrocyte zinc and 1 and 2 metallothionein gene expression. The assessment of body mass index (BMI) and abdominal circumference (AC) was performed, besides the analysis of dietary intake of patients. The majority of the evaluated patients presented overweight, before and after the treatment, with no significant difference between the times of the study. It was identified that the AC was significantly reduced in the group (p<0.05) after the intervention. The majority of the patients had intake below the recommendation of calories and fibers and above recommendation of proteins. The mono and polyunsaturated fats were adequate for the majority of the patients, however, the saturated fat and cholesterol were consumed in excess by a great part of the individuals. The intake of zinc was inadequate, being noticed an inadequacy of 100% in the male gender and of 84% in the female. After the treatment with rosuvastatin there was a significant reduction in the total cholesterol (TC) and LDL-c (p<0.01) and no alterations were observed in the HDL-c and triacylglycerols. It was also verified that the reduction of glycemia (p<0.05) and of hsCRP (p<0.01). The analysis did not demonstrate significant differences in the plasmatic and erythrocyte zinc concentration after the treatment. There was, after the treatment, reduction of the MT1F gene (p<0.05) without, however, occurring significant alterations in the MT2A gene. The treatment with rosuvastatin was effective in the reduction of TC and LDL-c, and promoted the reduction of inflammatory marker hsCRP. The zinc in the plasma and erythrocyte was not altered by the use of the medication and there was a reduction in the MT1F gene, possibly due to the reduction of inflammation. The majority of patients presented inadequate intake of zinc and this inadequacy did not have relation with the mineral parameters in plasma and erythrocytes or with the metallothionein gene expression |
id |
UFRN_9eb1fca8d2cc5c7cb09a76140b5c6c46 |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/13494 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Dias, Paula Cristina Silveirahttp://lattes.cnpq.br/0066564403217916http://lattes.cnpq.br/1863589790139155Rezende, Adriana Augusto dehttp://lattes.cnpq.br/4245215108740331Rebecchi, Ivanise Marina Morettihttp://lattes.cnpq.br/7308186244207080Ong, Thomas Prateshttp://lattes.cnpq.br/2216436678930586Schwarzschild, Lúcia de Fátima Campos Pedrosa2014-12-17T14:16:34Z2014-01-152014-12-17T14:16:34Z2011-02-22DIAS, Paula Cristina Silveira. Evaluation of the zinc status and the metallothionein gene expression in patients with atherosclerosis treated with rosuvastatin. 2011. 74 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2011.https://repositorio.ufrn.br/jspui/handle/123456789/13494The study had as objective to evaluate the zinc status by means of dietary intake, zinc in plasma and in erythrocytes and the metallothionein gene expression in patients with atherosclerosis in use of rosuvastatin. The research involved 27 adult and elderly patients of both genders with atherosclerosis that were treated with rosuvastatin (10mg/day) during 4 months. We performed the dosage of lipids, glucose, AST and ALT, ultrasensitive C-reactive protein (hsCRP), plasmatic and erythrocyte zinc and 1 and 2 metallothionein gene expression. The assessment of body mass index (BMI) and abdominal circumference (AC) was performed, besides the analysis of dietary intake of patients. The majority of the evaluated patients presented overweight, before and after the treatment, with no significant difference between the times of the study. It was identified that the AC was significantly reduced in the group (p<0.05) after the intervention. The majority of the patients had intake below the recommendation of calories and fibers and above recommendation of proteins. The mono and polyunsaturated fats were adequate for the majority of the patients, however, the saturated fat and cholesterol were consumed in excess by a great part of the individuals. The intake of zinc was inadequate, being noticed an inadequacy of 100% in the male gender and of 84% in the female. After the treatment with rosuvastatin there was a significant reduction in the total cholesterol (TC) and LDL-c (p<0.01) and no alterations were observed in the HDL-c and triacylglycerols. It was also verified that the reduction of glycemia (p<0.05) and of hsCRP (p<0.01). The analysis did not demonstrate significant differences in the plasmatic and erythrocyte zinc concentration after the treatment. There was, after the treatment, reduction of the MT1F gene (p<0.05) without, however, occurring significant alterations in the MT2A gene. The treatment with rosuvastatin was effective in the reduction of TC and LDL-c, and promoted the reduction of inflammatory marker hsCRP. The zinc in the plasma and erythrocyte was not altered by the use of the medication and there was a reduction in the MT1F gene, possibly due to the reduction of inflammation. The majority of patients presented inadequate intake of zinc and this inadequacy did not have relation with the mineral parameters in plasma and erythrocytes or with the metallothionein gene expressionO estudo teve como objetivo avaliar o status de zinco por meio da ingestão dietética, zinco no plasma e nos eritrócitos e a expressão gênica das metalotioneínas em pacientes com aterosclerose em uso de rosuvastatina. A pesquisa envolveu 27 pacientes adultos e idosos de ambos os sexos com aterosclerose que foram tratados com rosuvastatina (10mg/dia) durante 4 meses. Foi realizada a dosagem do perfil lipídico, glicemia, AST e ALT, proteína C reativa ultrasensível (PCRus), zinco plasmático e eritrocitário e expressão gênica das metalotioneínas 1 e 2. Realizou-se a avaliação do índice de massa corporal (IMC) e circunferência abdominal (CA), além da análise do consumo alimentar dos pacientes. A maioria dos pacientes avaliados apresentou sobrepeso, tanto antes como após o tratamento, sem diferença significativa entre os tempos do estudo. Identificou-se que a CA foi reduzida significativamente no grupo (p<0,05) após a intervenção. A maioria dos pacientes tinha ingestão abaixo da recomendação de calorias e fibras e acima do recomendado de proteínas. As gorduras mono e poliinsaturadas foram adequadas para a maioria dos pacientes, no entanto, a gordura saturada e colesterol foram consumidos em excesso por grande parte dos indivíduos. O consumo de zinco foi inadequado, constatando-se 100% de inadequação no sexo masculino e 84% no feminino. Após o tratamento com a rosuvastatina houve redução significativa do colesterol total (CT) e LDL-c (p<0,01) e não foram observadas alterações no HDL-c e triacilglicérides. Foi verificada também a redução da glicemia (p<0,05) e da PCRus (p<0,01). As análises não demonstraram diferenças significativas nas concentrações de zinco no plasma nem nos eritrócitos antes e após o tratamento com rosuvastatina. Houve, após o tratamento, redução do gene MT1F (p<0,05) sem, no entanto, ocorrer alteração significativa do gene MT2A. O tratamento com rosuvastatina foi efetivo na redução do CT e LDL-c, bem como promoveu a redução do marcador inflamatório PCRus. O zinco no plasma e nos eritrócitos não foi alterado pelo uso da medicamento e houve uma redução do gene MT1F, possivelmente em função da redução da inflamação. A maioria dos pacientes apresentou consumo inadequado de zinco e esta inadequação não teve relação com os parâmetros do mineral no plasma ou nos eritrócitos nem com a expressão gênica das metalotioneínasConselho Nacional de Desenvolvimento Científico e Tecnológicoapplication/pdfporUniversidade Federal do Rio Grande do NortePrograma de Pós-Graduação em Ciências FarmacêuticasUFRNBRBioanálises e MedicamentosAterosclerose. Rosuvastatina. Zinco. MetalotioneínasAtherosclerosis. Rosuvastatin. Zinc. MetallothioneinCNPQ::CIENCIAS DA SAUDE::FARMACIAAvaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatinaEvaluation of the zinc status and the metallothionein gene expression in patients with atherosclerosis treated with rosuvastatininfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALAvaliacaoStatusZinco_Dias_2011.pdfapplication/pdf2575213https://repositorio.ufrn.br/bitstream/123456789/13494/1/AvaliacaoStatusZinco_Dias_2011.pdfb1a82c5d30ff9ebaa0fce4e2c1fef958MD51TEXTPaulaCSD_DISSERT.pdf.txtPaulaCSD_DISSERT.pdf.txtExtracted texttext/plain112542https://repositorio.ufrn.br/bitstream/123456789/13494/6/PaulaCSD_DISSERT.pdf.txt5c6d949c9581b3346c46f97a32ebf27aMD56AvaliacaoStatusZinco_Dias_2011.pdf.txtAvaliacaoStatusZinco_Dias_2011.pdf.txtExtracted texttext/plain112098https://repositorio.ufrn.br/bitstream/123456789/13494/8/AvaliacaoStatusZinco_Dias_2011.pdf.txt6194e63765e5a782941661605a5c957bMD58THUMBNAILPaulaCSD_DISSERT.pdf.jpgPaulaCSD_DISSERT.pdf.jpgIM Thumbnailimage/jpeg2085https://repositorio.ufrn.br/bitstream/123456789/13494/7/PaulaCSD_DISSERT.pdf.jpgbd6692a3510ce70b938727fd31a049d8MD57AvaliacaoStatusZinco_Dias_2011.pdf.jpgAvaliacaoStatusZinco_Dias_2011.pdf.jpgGenerated Thumbnailimage/jpeg1261https://repositorio.ufrn.br/bitstream/123456789/13494/9/AvaliacaoStatusZinco_Dias_2011.pdf.jpgee29a6bc489f17d1afba4275ae74c1c2MD59123456789/134942019-05-26 02:22:54.775oai:https://repositorio.ufrn.br:123456789/13494Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2019-05-26T05:22:54Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.por.fl_str_mv |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
dc.title.alternative.eng.fl_str_mv |
Evaluation of the zinc status and the metallothionein gene expression in patients with atherosclerosis treated with rosuvastatin |
title |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
spellingShingle |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina Dias, Paula Cristina Silveira Aterosclerose. Rosuvastatina. Zinco. Metalotioneínas Atherosclerosis. Rosuvastatin. Zinc. Metallothionein CNPQ::CIENCIAS DA SAUDE::FARMACIA |
title_short |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
title_full |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
title_fullStr |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
title_full_unstemmed |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
title_sort |
Avaliação do status de zinco e da expressão gênica de metalotioneínas em pacientes com aterosclerose tratados com rosuvastatina |
author |
Dias, Paula Cristina Silveira |
author_facet |
Dias, Paula Cristina Silveira |
author_role |
author |
dc.contributor.authorID.por.fl_str_mv |
|
dc.contributor.authorLattes.por.fl_str_mv |
http://lattes.cnpq.br/0066564403217916 |
dc.contributor.advisorID.por.fl_str_mv |
|
dc.contributor.advisorLattes.por.fl_str_mv |
http://lattes.cnpq.br/1863589790139155 |
dc.contributor.referees1.pt_BR.fl_str_mv |
Rezende, Adriana Augusto de |
dc.contributor.referees1ID.por.fl_str_mv |
|
dc.contributor.referees1Lattes.por.fl_str_mv |
http://lattes.cnpq.br/4245215108740331 |
dc.contributor.referees2.pt_BR.fl_str_mv |
Rebecchi, Ivanise Marina Moretti |
dc.contributor.referees2ID.por.fl_str_mv |
|
dc.contributor.referees2Lattes.por.fl_str_mv |
http://lattes.cnpq.br/7308186244207080 |
dc.contributor.referees3.pt_BR.fl_str_mv |
Ong, Thomas Prates |
dc.contributor.referees3ID.por.fl_str_mv |
|
dc.contributor.referees3Lattes.por.fl_str_mv |
http://lattes.cnpq.br/2216436678930586 |
dc.contributor.author.fl_str_mv |
Dias, Paula Cristina Silveira |
dc.contributor.advisor1.fl_str_mv |
Schwarzschild, Lúcia de Fátima Campos Pedrosa |
contributor_str_mv |
Schwarzschild, Lúcia de Fátima Campos Pedrosa |
dc.subject.por.fl_str_mv |
Aterosclerose. Rosuvastatina. Zinco. Metalotioneínas |
topic |
Aterosclerose. Rosuvastatina. Zinco. Metalotioneínas Atherosclerosis. Rosuvastatin. Zinc. Metallothionein CNPQ::CIENCIAS DA SAUDE::FARMACIA |
dc.subject.eng.fl_str_mv |
Atherosclerosis. Rosuvastatin. Zinc. Metallothionein |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::FARMACIA |
description |
The study had as objective to evaluate the zinc status by means of dietary intake, zinc in plasma and in erythrocytes and the metallothionein gene expression in patients with atherosclerosis in use of rosuvastatin. The research involved 27 adult and elderly patients of both genders with atherosclerosis that were treated with rosuvastatin (10mg/day) during 4 months. We performed the dosage of lipids, glucose, AST and ALT, ultrasensitive C-reactive protein (hsCRP), plasmatic and erythrocyte zinc and 1 and 2 metallothionein gene expression. The assessment of body mass index (BMI) and abdominal circumference (AC) was performed, besides the analysis of dietary intake of patients. The majority of the evaluated patients presented overweight, before and after the treatment, with no significant difference between the times of the study. It was identified that the AC was significantly reduced in the group (p<0.05) after the intervention. The majority of the patients had intake below the recommendation of calories and fibers and above recommendation of proteins. The mono and polyunsaturated fats were adequate for the majority of the patients, however, the saturated fat and cholesterol were consumed in excess by a great part of the individuals. The intake of zinc was inadequate, being noticed an inadequacy of 100% in the male gender and of 84% in the female. After the treatment with rosuvastatin there was a significant reduction in the total cholesterol (TC) and LDL-c (p<0.01) and no alterations were observed in the HDL-c and triacylglycerols. It was also verified that the reduction of glycemia (p<0.05) and of hsCRP (p<0.01). The analysis did not demonstrate significant differences in the plasmatic and erythrocyte zinc concentration after the treatment. There was, after the treatment, reduction of the MT1F gene (p<0.05) without, however, occurring significant alterations in the MT2A gene. The treatment with rosuvastatin was effective in the reduction of TC and LDL-c, and promoted the reduction of inflammatory marker hsCRP. The zinc in the plasma and erythrocyte was not altered by the use of the medication and there was a reduction in the MT1F gene, possibly due to the reduction of inflammation. The majority of patients presented inadequate intake of zinc and this inadequacy did not have relation with the mineral parameters in plasma and erythrocytes or with the metallothionein gene expression |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011-02-22 |
dc.date.accessioned.fl_str_mv |
2014-12-17T14:16:34Z |
dc.date.available.fl_str_mv |
2014-01-15 2014-12-17T14:16:34Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
DIAS, Paula Cristina Silveira. Evaluation of the zinc status and the metallothionein gene expression in patients with atherosclerosis treated with rosuvastatin. 2011. 74 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2011. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/jspui/handle/123456789/13494 |
identifier_str_mv |
DIAS, Paula Cristina Silveira. Evaluation of the zinc status and the metallothionein gene expression in patients with atherosclerosis treated with rosuvastatin. 2011. 74 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2011. |
url |
https://repositorio.ufrn.br/jspui/handle/123456789/13494 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal do Rio Grande do Norte |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UFRN |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Bioanálises e Medicamentos |
publisher.none.fl_str_mv |
Universidade Federal do Rio Grande do Norte |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/13494/1/AvaliacaoStatusZinco_Dias_2011.pdf https://repositorio.ufrn.br/bitstream/123456789/13494/6/PaulaCSD_DISSERT.pdf.txt https://repositorio.ufrn.br/bitstream/123456789/13494/8/AvaliacaoStatusZinco_Dias_2011.pdf.txt https://repositorio.ufrn.br/bitstream/123456789/13494/7/PaulaCSD_DISSERT.pdf.jpg https://repositorio.ufrn.br/bitstream/123456789/13494/9/AvaliacaoStatusZinco_Dias_2011.pdf.jpg |
bitstream.checksum.fl_str_mv |
b1a82c5d30ff9ebaa0fce4e2c1fef958 5c6d949c9581b3346c46f97a32ebf27a 6194e63765e5a782941661605a5c957b bd6692a3510ce70b938727fd31a049d8 ee29a6bc489f17d1afba4275ae74c1c2 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1802117590081863680 |